Intel's upcoming earnings could reflect recent improvements, but there's risk that customers are shifting budgets away from the company's bread and butter.
Intel Corp.’s upcoming earnings report could reflect recent improvements made by the company, but a Susquehanna Financial Group analyst still has questions about the chip company’s artificial-intelligence narrative.
Susquehanna’s Christopher Rolland is encouraged by “improving dynamics” in the client and Chromebook markets that could help Intel INTC deliver second-quarter earnings within the top half of its forecasted range and offer an outlook that may be “slightly better” than the consensus view. Though Rolland boosted his price target on Intel shares to $35 from $33 Wednesday, he maintained a neutral rating, expressing concern about the company’s positioning in the world of AI.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AMD may suffer from elevated expectations — but Wells Fargo is warming to Intel's setupChip companies are getting ready to report results, but when it comes to the all-important outlook, AMD may suffer from aggressive expectations.
Read more »
Intel's powerful CPUs won't be coming out until 2024 | Digital TrendsIntel's internal performance projections confirm Arrow Lake desktop CPUs will be arriving next year.
Read more »
Intel mini NUC computers get a second life thanks to AsusAsus can build new NUC computers based on future Intel chips
Read more »
How Games like Dordogne Use Mixed Media to Explore Family Dynamics in a Nuanced WayGames like Dordogne, The Last of Us, and Gone Home have used mixed media to signify and explore family dynamics across different generations. It's something games are uniquely able to do, writes phoenixsimms.
Read more »
Breakingviews - Argenx drug boost is mixed blessing for suitorsArgenx has long been a presumed takeover target for drugmakers like Pfizer . The 23 billion euro ($26 billion) Belgian biotechnology company is in an attractive position for many Big Pharma companies like $240 billion AbbVie , which are facing patent cliffs later in the decade. Meanwhile, Argenx is working on cures for rare diseases like chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disorder, as well as well as myasthenia gravis, a degenerative disease. Many of its remedies like Vyvgart, which delivered positive drug trial results on Monday, are likely to reach their peak just as the big drugmakers’ revenues come under patent pressure.
Read more »
Chair Gensler says SEC reaction to Ripple decision is mixed, still under considerationU.S. Securities and Exchange Commission chair Gary Gensler made his first public statements about the recent ruling in the SEC suit against Ripple Labs, but he had few comments.
Read more »